TY  - GEN
A1  - Fekete, Stefanie
A1  - Egberts, K.
A1  - Preissler, T.
A1  - Wewetzer, C.
A1  - Mehler-Wex, C.
A1  - Romanos, M.
A1  - Gerlach, M.
T1  - Correction to: Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride
T2  - European Journal of Clinical Pharmacology
N2  - Correction to: European Journal of Clinical Pharmacology (2021) 77:163–170 https://doi.org/10.1007/s00228-020-03000-0
KW  - Erratum
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-329467
VL  - 77
IS  - 8
ER  - 
TY  - JOUR
A1  - Fekete, Stefanie
A1  - Egberts, K.
A1  - Preissler, T.
A1  - Wewetzer, C.
A1  - Mehler-Wex, C.
A1  - Romanos, M.
A1  - Gerlach, M.
T1  - Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride
JF  - European Journal of Clinical Pharmacology
N2  - Purpose
Tiapride is commonly used in Europe for the treatment of tics. The aim of this study was to examine the relationship between dose and serum concentrations of tiapride and potential influential pharmacokinetic factors in children and adolescents. In addition, a preliminary therapeutic reference range for children and adolescents with tics treated with tiapride was calculated.

Methods
Children and adolescents treated with tiapride at three university hospitals and two departments of child and adolescents psychiatry in Germany and Austria were included in the study. Patient characteristics, doses, serum concentrations, and therapeutic outcome were assessed during clinical routine care using standardised measures.

Results
In the 49 paediatric patients (83.7% male, mean age = 12.5 years), a positive correlation was found between tiapride dose (median 6.9 mg/kg, range 0.97–19.35) and serum concentration with marked inter-individual variability. The variation in dose explained 57% of the inter-patient variability in tiapride serum concentrations; age, gender, and concomitant medication did not contribute to the variability. The symptoms improved in 83.3% of the patients. 27.1% of the patients had mild or moderate ADRs. No patient suffered from severe ADRs.

Conclusions
This study shows that tiapride treatment was effective and safe in most patients with tics. Compared with the therapeutic concentration range established for adults with Chorea Huntington, our data hinted at a lower lower limit (560 ng/ml) and similar upper limit (2000 ng/ml).
KW  - Tourette syndrome
KW  - therapeutic drug monitoring
KW  - serum concentration
KW  - paediatrics
KW  - pharmacokinetics
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-279893
VL  - 77
IS  - 2
ER  -